- Home
- IDYA vs KYN Comparison
IDYA vs KYN Comparison
Compare IDYA & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- KYN
- Stock Information
- Founded
- IDYA 2015
- KYN 2004
- Country
- IDYA United States
- KYN United States
- Employees
- IDYA N/A
- KYN N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- KYN Finance/Investors Services
- Sector
- IDYA Health Care
- KYN Finance
- Exchange
- IDYA Nasdaq
- KYN Nasdaq
- Market Cap
- IDYA 1.9B
- KYN 2.0B
- IPO Year
- IDYA 2019
- KYN N/A
- Fundamental
- Price
- IDYA $21.23
- KYN $12.79
- Analyst Decision
- IDYA Strong Buy
- KYN
- Analyst Count
- IDYA 13
- KYN 0
- Target Price
- IDYA $53.42
- KYN N/A
- AVG Volume (30 Days)
- IDYA 1.1M
- KYN 561.5K
- Earning Date
- IDYA 08-05-2025
- KYN 01-01-0001
- Dividend Yield
- IDYA N/A
- KYN 8.99%
- EPS Growth
- IDYA N/A
- KYN N/A
- EPS
- IDYA N/A
- KYN 0.71
- Revenue
- IDYA $7,000,000.00
- KYN N/A
- Revenue This Year
- IDYA $101.20
- KYN N/A
- Revenue Next Year
- IDYA $286.70
- KYN N/A
- P/E Ratio
- IDYA N/A
- KYN $13.79
- Revenue Growth
- IDYA N/A
- KYN N/A
- 52 Week Low
- IDYA $13.45
- KYN $7.84
- 52 Week High
- IDYA $44.42
- KYN $9.88
- Technical
- Relative Strength Index (RSI)
- IDYA 62.23
- KYN 58.66
- Support Level
- IDYA $21.08
- KYN $12.18
- Resistance Level
- IDYA $22.37
- KYN $12.56
- Average True Range (ATR)
- IDYA 0.92
- KYN 0.17
- MACD
- IDYA -0.09
- KYN 0.01
- Stochastic Oscillator
- IDYA 61.72
- KYN 76.74
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About KYN Kayne Anderson Energy Infrastructure Fund Inc.
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.